Pharmafile Logo
Pharmafocus logo
Advanced Search

Romosozumab

Showing 4 posts of 4 posts found.

amgen_hq

Amgen hit by major safety blow on osteoporosis drug

May 22, 2017
Research and Development, Sales and Marketing Amgen, Romosozumab, UCB SA

Amgen and UCB SA have been delivered a crushing blow in its attempt to have a drug for osteoporosis approved …

News
tablet_production_2

Further positive trial results boost Amgen and UCB’s romosozumab

March 21, 2016
Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval

Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …

News
ucb_logo_and_chief_executive

UCB targets regulatory filing for its osteoporosis drug in 2016

March 3, 2016
Medical Communications, Research and Development, Sales and Marketing Romosozumab, UCB Pharma, osteoporosis

Belgian drug company UCB says it is looking at a regulatory filing for its trial drug romosozumab to treat osteoporosis …

News
amgen_ucb

Amgen and UCB announce positive romosozumab results

February 22, 2016
Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis

Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026